![Jan Nilsson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jan Nilsson
Direktor/Vorstandsmitglied bei Aptahem AB
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Bert Roland Kari Junno | M | 58 |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
Knut Mikael Ingolf Lindstam | M | 58 |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 Jahre |
Johan Lindh | M | - |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 Jahre |
Theresa Comiskey Olsen | F | 61 |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
Luiza Jedlina | M | - |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 Jahre |
Ulla Cristina Glad | M | 72 |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 8 Jahre |
Ola Skanung | M | 60 |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
Maria Ekblad | F | - |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 2 Jahre |
Ingela Hallberg | M | 69 |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 2 Jahre |
Suzanne Kilany | F | - |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
Åsa Kornfeld | F | - |
Aptahem AB
![]() Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Schweden | 11 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Jan Nilsson
- Persönliches Netzwerk